ADMA Biologics, Inc.

NASDAQ:ADMA

Biotechnology

Healthcare
$13.56 +0.42%

+$0.04 today

Market cap
$3.01B
Beta
0.73
P/E (TTM)
12.1
EPS (TTM)
$0.70
52W Low $7.21High $20.46

Volume 3.17M

Average 7.07M

ADMA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ADMA Biologics, Inc.NASDAQ: ADMA

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 69.4%

Gross margin was 69.4% in Q2 FY2026, up 14.2 pp from a year earlier. On a trailing-twelve-month basis it was 64.7%, up 11.7 pp year over year. Over 3 fiscal years it widened by 34.5 pp.

Context

  • Gross margin widened in 3 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
69.4%-1.2 pp QoQ
Last fiscal yearDec 2025
57.4%+5.9 pp YoY
LTMJun 2026
64.7%+11.7 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+14.2 pp——
1 year+5.9 pp——
3 years+34.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
57.4%
Year-over-year change
+5.9pp

Gross Margin vs competitors

How ADMA compares with its peers on the latest reported figures

  • ADMA's LTM Jun 2026 gross margin of 64.7% is the 3rd highest of the 4 companies compared; the peer median is 92.0%.
  • Its year-over-year change of +11.7 pp is the 2nd highest of 4, against a peer median of -1.3 pp.
  • Over three fiscal years its change of +34.5 pp compares with a peer median of -1.7 pp.
ADMA Competitors Peer median
Gross Margin for ADMA and competitors
Company Period LTM level YoY 3-year change
ABUSArbutus Biopharma CorporationLTM Mar 2026100.0% +277.5 pp-2.6 pp
IVVDInvivyd, Inc.LTM Mar 202692.0% -1.3 pp—
ADMAADMA Biologics, Inc.LTM Jun 202664.7% +11.7 pp+34.5 pp
GRFSGrifols, S.A.LTM Jun 202637.2% -2.3 pp-0.8 pp
Peer median (excluding ADMA) 92.0%-1.3 pp-1.7 pp

Competitors are the stored peer set for ADMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue80.94M154.08M258.22M426.45M510.17M
Cost of Revenue79.77M118.82M169.27M206.9M217.41M
Gross Profit1.17M35.27M88.94M219.55M292.77M
Gross Margin1.4%22.9%34.4%51.5%57.4%
Research & Development3.65M3.61M3.3M1.81M4.76M
Selling, General & Admin42.9M52.46M59.02M74.12M91.58M
Operating Expenses59.55M74.63M67.31M80.57M101.32M
Depreciation & Amortization5.5M7.11M8.33M8.05M8.1M
EBITDA(53.1M)(39.51M)5.12M147.69M197.86M
EBITDA Margin-65.6%-25.6%2.0%34.6%38.8%
Operating Income(58.37M)(39.37M)21.63M138.98M191.44M
Operating Margin-72.1%-25.5%8.4%32.6%37.5%
Interest Income34.53K44.83K1.62M2.1M1.87M
Interest Expense13.06M19.28M25.03M13.93M7.11M
Other Income / Expenses(13.27M)(26.54M)(49.87M)(13.27M)(8.79M)
Income Before Tax(71.65M)(65.9M)(28.24M)125.71M182.66M
Pre-Tax Margin-88.5%-42.8%-10.9%29.5%35.8%
Income Tax Expense000(71.96M)35.73M
Net Income(71.65M)(65.9M)(28.24M)197.67M146.93M
Net Margin-88.5%-42.8%-10.9%46.4%28.8%
EPS (Basic)(0.61)(0.43)(0.13)0.850.62
EPS (Diluted)(0.61)(0.43)(0.13)0.810.60
Weighted Avg Shares139.58M197.87M223.98M233.08M238.3M
Weighted Avg Shares (Diluted)139.58M197.87M223.98M243.34M244.9M

ADMA Biologics, Inc.

NASDAQ:ADMA

Intrinsic Alpha fair value

Locked

Current Price

$13.56

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.